Leerink Healthcare Conference

Investor Overview

Safe harbor statement

This presentation contains “forward-looking statements,” which are statements related to future events that by their nature address matters that are uncertain. All forward-looking information is inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, please refer to our reports filed with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the period ended September 30, 2018. Forward-looking statements address our expected future business, financial performance, financial condition as well as results of operations, and often contain words such as “intends,” “estimates,” “anticipates,” “hopes,” “projects,” “plans,” “expects,” “seek,” “believes,” "see," “should,” “will,” “would,” “target,” and similar expressions and the negative versions thereof. Such statements are based only upon our current expectations. Any forward-looking statement speaks only as of the date made. Reliance should not be placed on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those expressed or implied. Forward-looking statements include statements that address activities, events or developments that we expect, believes or anticipate will or may occur in the future. Forward-looking statements are based on our experience and perception of current conditions, trends, expected future developments and other factors we believe are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond our control. We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.

The mission of Guardant Health is to **conquer cancer with data**

Expanding precision oncology to all stages of disease through easier access to cancer's underlying molecular information



1 YTD as of September 30, 2018 compared to nine-months ended 2017

Realizing the $35B+ U.S. opportunity requires delivering the right information for the right intervention for the right patient population

U.S. Patient Population	Advanced-Stage Cancer ~700 K	Cancer Survivors ~15 million	Asymptomatic, Hi-Risk ~35 million
Information	Therapy Selection GUARDANT360 OMNI	Recurrence Monitoring LUNAR - 1	Screening & Early Detection LUNAR - 2
Intervention	Targeted & Immuno-oncology therapies 50+ biopharma companies	Neoadjuvant, Adjuvant, or Curative	Curative or Preventative
U.S. Market Size	~$6B	~$15B	~$18B

Source: CDC Statistics; US Census; American Cancer Society, Cancer Facts and Statistics; SEER; Rebecca L. Siegel, Cancer Statistics, 2018, A Cancer Journal for Clinicals, 68:7; Piper Jaffray, Liquid Biopsy Report, Cowen Equity Research, Foundation Medicine, dated March 18, 2018; CDC, Viral Hepatitis and Liver Cancer report.
Note: Market sizing based on Guardant Health internal analysis.

Liquid biopsy for therapy selection in advanced cancer

GUARDANT360®

Market leading Comprehensive Liquid Biopsy

Guideline-complete clinical results for **advanced solid tumors** in less than 7 days


GUARDANT360™

REPORTING
Final Report Date: SEP-06-2016
Receipt Date: AUG-31-2016
Collection Date: AUG-30-2016
Specimen: Blood
Status: Final

PHYSICIAN
Mary Smith, MD
Account: Boca Raton Regional Hospital
Address: 1st Street, San Francisco, CA 94155
Ph: 310.829.8265 | Fax: 310.829.1111
Additional Recipient: N/A

Complete Tumor Response Map on page 2

Summary of Somatic Alterations & Associated Treatment Options

KEY: Lack of response · Approved in indication · Approved in other indication

Alteration	% cfDNA or Amplification	Associated FDA-approved therapies	Clinical trial availability (see page 3)
EGFR T790M	0.7%	Osimertinib Erlotinib, Gefitinib, Afatinib	Yes - Nearby
EGFR E746_A750del (Exon 19 Deletion)	12.2%	None	Yes - None Nearby
EML4-ALK Fusion	5.0%	Crizotinib	Yes - None Nearby
CDK6 Amplification	Medium (++)	Palbociclib	Yes - None Nearby
EGFR Amplification	Low (+)	Afatinib, Cabozantinib, Necitumumab, Panitumumab	Yes - None Nearby
TP53 T231fs	11.0%	None	Yes - None Nearby

Variants of Uncertain Significance
EGFR L862M (0.4%), *NOTCH1* P2439S (0.2%)
Functional consequences and clinical significance of alterations unknown. Relevance of therapies targeting these alterations uncertain.

Synonymous Alterations
EGFR L858L (0.4%)
This sequence change does not alter the amino acid at this position and is unlikely to be a therapeutic target. Clinical correlation is advised.

We evaluated 73 genes, including the following guideline-recommended genes for NSCLC:

EGFR (T790M and others)	*ALK*	*ROS1*	*BRAF*	*MET*	*ERBB2* (HER2)	*RET*

GUARDANT OMNI™

>2MB footprint panel tailored for **immuno-oncology** and **targeted therapy** development

MERCK MERCK Pfizer

AstraZeneca Bristol-Myers Squibb

Establishing a blood first paradigm in advanced cancer



NILE: Guardant360 vs tissue standard of care in 1st-line NSCLC

Primary endpoint met; Guardant360 performance matches tissue testing detection rates; delivers faster turnaround time




GUARDANT™